Source: Journal of thoracic oncology. Conference titles: World Conference on Lung Cancer. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, POLIMORFISMO, ADENOCARCINOMA, MUTAÇÃO, METÁSTASE NEOPLÁSICA
ABNT
CAIRES-LIMA, Rafael et al. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 07 nov. 2024. , 2013APA
Caires-Lima, R., Protasio, B. M., Takahashi, T. K., Mak, M. P., Nakazato, D., Mesquita, C. S., et al. (2013). Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. Faculdade de Medicina, Universidade de São Paulo.NLM
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2024 nov. 07 ]Vancouver
Caires-Lima R, Protasio BM, Takahashi TK, Mak MP, Nakazato D, Mesquita CS, Takagaki TY, Soares IC, Mello ES, Hoff PM, Alves VA, Castro Jr. G. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations, in Sao Paulo - Brazil. Journal of thoracic oncology. 2013 ; 8 S892.[citado 2024 nov. 07 ]